person · Reporting owner

HOLLAND CHRISTOPHER S

Disclosed activity across 3 companies

Tapewire entity: 24143
SEC CIK: 0001271440

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
JABIL INCJBL · Entity 3138	Director	April 07, 2026	April 07, 2026
STERIS plcSTE · Entity 3228	Director	August 10, 2026	August 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

JABIL INC

Report date April 07, 2026 · Filed April 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,150	Reported balance After 2026-04-07 transaction · row 1 1 source row Row 1 · 2026-04-07 · Gift · Disposed 960 · Balance 11,150

STERIS plc

Report date August 10, 2026 · Filed August 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Career Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	5,989	Reported balance After 2026-08-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-08-10 · Grant · Acquired 1,025 · Balance 5,989 F1: Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. F2: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service.

Filing footnotes · ownership attribution and instrument terms

F1: Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service.

F2: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BARD C R INC /NJ/

Report date December 29, 2017 · Filed January 03, 2018

Section 16 reporting ended · disclosed 2018-01-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	44,904.363	Reported balance After 2017-12-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-12-29 · Grant · Acquired 17,913 · Balance 44,904.363 F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). All of the transactions reported in this Form 4 occurred simultaneously upon the closing of the Merger. F2: Includes 17,913 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units.
Common StockSEC Table I · non-derivative	Direct	51,912.363	Reported balance After 2017-12-29 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2017-12-29 · Grant · Acquired 7,008 · Balance 51,912.363 F3: Includes 7,008 Bard restricted stock units deemed acquired upon satisfaction of performance goals that were considered achieved upon the closing of the Merger.
Common StockSEC Table I · non-derivative	Direct	50,944	Reported balance After 2017-12-29 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2017-12-29 · Disposition to issuer · Disposed 968.363 · Balance 50,944 F4: Includes 968.363 shares of Bard common stock that, upon the closing of the Merger, were cancelled and converted into the right to receive the Merger Consideration.
Common StockSEC Table I · non-derivative	Direct	40,673	Reported balance After 2017-12-29 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2017-12-29 · Disposition to issuer · Disposed 10,271 · Balance 40,673 F5: Includes 10,271 Bard restricted stock units that, upon the closing of the Merger, were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent adjusted BD restricted stock units.
Common StockSEC Table I · non-derivative	Direct	22,760	Reported balance After 2017-12-29 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2017-12-29 · Disposition to issuer · Disposed 17,913 · Balance 22,760 F2: Includes 17,913 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-12-29 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2017-12-29 · Disposition to issuer · Disposed 22,760 · Balance 0 F6: Includes 22,760 shares of restricted stock units acquired through deferral of compensation under Bard's Management Stock Purchase Program ("MSPP"). In accordance with the Merger Agreement (i) each Bard MSPP Unit that by its terms vested and/or became payable at the closing of the Merger was cancelled and converted into, with respect to each share of Bard common stock underlying such Bard MSPP Unit, the right to receive the Merger Consideration; and (ii) each Bard MSPP Unit that did not, by its terms, become payable at the closing of the Merger was assumed and converted in accordance with the exchange ratio set forth in the Merger Agreement into an equivalent adjusted BD MSPP Unit.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $186.43 · Expires 2025-12-09	Direct	0	Reported balance After 2017-12-29 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-12-29 · Disposition to issuer · Disposed 17,562 · Balance 0 F7: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $168.87 · Expires 2024-12-10	Direct	0	Reported balance After 2017-12-29 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-12-29 · Disposition to issuer · Disposed 18,837 · Balance 0 F7: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $136.37 · Expires 2023-12-11	Direct	0	Reported balance After 2017-12-29 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-12-29 · Disposition to issuer · Disposed 5,944 · Balance 0 F7: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $219.56 · Expires 2026-12-14	Direct	0	Reported balance After 2017-12-29 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2017-12-29 · Disposition to issuer · Disposed 15,279 · Balance 0 F7: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). All of the transactions reported in this Form 4 occurred simultaneously upon the closing of the Merger.

F2: Includes 17,913 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units.

F3: Includes 7,008 Bard restricted stock units deemed acquired upon satisfaction of performance goals that were considered achieved upon the closing of the Merger.

F4: Includes 968.363 shares of Bard common stock that, upon the closing of the Merger, were cancelled and converted into the right to receive the Merger Consideration.

F5: Includes 10,271 Bard restricted stock units that, upon the closing of the Merger, were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent adjusted BD restricted stock units.

F6: Includes 22,760 shares of restricted stock units acquired through deferral of compensation under Bard's Management Stock Purchase Program ("MSPP"). In accordance with the Merger Agreement (i) each Bard MSPP Unit that by its terms vested and/or became payable at the closing of the Merger was cancelled and converted into, with respect to each share of Bard common stock underlying such Bard MSPP Unit, the right to receive the Merger Consideration; and (ii) each Bard MSPP Unit that did not, by its terms, become payable at the closing of the Merger was assumed and converted in accordance with the exchange ratio set forth in the Merger Agreement into an equivalent adjusted BD MSPP Unit.

F7: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 28, 2016 Filed Oct 31, 2016 16:34 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionOption (Right to Buy) · Derivative	3,971	$0.00 Strike: $95.99	$0.00	Disclosure SEC source: 0001225208-16-040863 · doc4.xml · derivative · entry 5 HOLLAND CHRISTOPHER S · CIK 0001271440 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,971 shares Expires 2022-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F7 · derivative.exercise_date: Options fully vested and are currently exercisable. Read SEC document
October 28, 2016 Filed Oct 31, 2016 16:34 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	2,825	$210.18	$593,756.52	Disclosure SEC source: 0001225208-16-040863 · doc4.xml · nonDerivative · entry 4 HOLLAND CHRISTOPHER S · CIK 0001271440 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,964.616 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F5 · price: Represents the weighted average sales price for price increments ranging from $210.00 to $210.41. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
October 28, 2016 Filed Oct 31, 2016 16:34 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	1,503	$211.34	$317,638.31	Disclosure SEC source: 0001225208-16-040863 · doc4.xml · nonDerivative · entry 3 HOLLAND CHRISTOPHER S · CIK 0001271440 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,789.616 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F4 · price: Represents the weighted average sales price for price increments ranging from $211.08 to $211.95. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
October 28, 2016 Filed Oct 31, 2016 16:34 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	1,396	$212.78	$297,037.95	Disclosure SEC source: 0001225208-16-040863 · doc4.xml · nonDerivative · entry 2 HOLLAND CHRISTOPHER S · CIK 0001271440 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,292.616 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F3 · price: Represents the weighted average sales price for price increments ranging from $212.39 to $213.07. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
October 28, 2016 Filed Oct 31, 2016 16:34 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionCommon Stock	3,971	$95.99	$381,176.29	Disclosure SEC source: 0001225208-16-040863 · doc4.xml · nonDerivative · entry 1 HOLLAND CHRISTOPHER S · CIK 0001271440 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,688.616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F2 · balance_after: Includes 80.455 shares acquired under the Company's Employee Stock Purchase Plan from May 17, 2016 to August 1, 2016. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.